Clinical Next-Gen Sequencing Will Usher in Changes for Vendors, Execs Say at Burrill Conference | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – As next-generation sequencing makes its way into the clinic, platform vendors will need to change their operations to accommodate the shift, company executives said this week at the Burrill Personalized Medicine Meeting held in Burlingame, Calif.

Those changes include new emphases on different geographies, as well as disease areas, and new approaches to handling the data.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.